Erudio Healtherudio.com
Clinical trial · no report yet · Early phase 1
SPARC-1
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma
- NCT04028245 ↗
- Completed
- Columbia University
- Focused
We haven't built an HCP commentary report on SPARC-1 (spartalizumab plus canakinumab in localized clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SPARC-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)
- Phase
- Early phase 1
- Status
- Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Spartalizumab; Canakinumab
- Arms
- Spartalizumab and Canakinumab · Experimental
- Enrollment
- 17
- Primary outcomes
- Percentage of subjects who proceed to radical nephrectomy
- Sponsor
- Columbia University with Novartis
- Start
- Aug 15, 2019
- Primary completion
- Mar 14, 2025
- Results posted
- No
- Registry record
- NCT04028245 · updated Apr 15, 2026